Cargando…

Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors

Purpose. The prognosis of advanced soft tissue sarcoma is poor, only a few drugs showing some activity with response rates around 15– 25%. Consequently drug development seems mandatory to improve treatment outcome. Following previous favourable EORTC experience, the Italian Group on Rare Tumors star...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santoro, Armando, Romanini, Antonella, Rosso, Alberto, Frustaci, Sergio, Comandone, Alessandro, Apice, Gaetano, De Toma, Domenico, Dogliotti, Luigi, Lionetto, Rita, Dani, Carla, Bruzzi, Paolo, Piolini, Marco, Bergnolo, Paola, Verusio, Claudio
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 1999
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395431/ https://www.ncbi.nlm.nih.gov/pubmed/18521282 http://dx.doi.org/10.1080/13577149977613

Ejemplares similares

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group
por: Palmerini, Emanuela, et al.
Publicado: (2021)

Trabectedin use in soft‐tissue sarcoma patients in a real‐world setting: Data from an Italian national drug‐access registry
por: Vincenzi, Bruno, et al.
Publicado: (2022)

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
por: Dickson, Mark A., et al.
Publicado: (2015)

Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
por: Lee, Ha-young, et al.
Publicado: (2012)

Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
por: Choi, Yunjung, et al.
Publicado: (2018)

A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)
por: Kalofonos, Haralabos P., et al.
Publicado: (2004)

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
por: Sobrero, A, et al.
Publicado: (2005)

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
por: Sobrero, A, et al.
Publicado: (2005)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas
por: Attia, Steven, et al.
Publicado: (2023)

A Phase II Study of Docetaxel in Chemotherapy-Naïve Patients With Recurrent or Metastatic Adult Soft Tissue Sarcoma
por: Bramwell, Vivien, et al.
Publicado: (1998)

Sarcoma Spheroids and Organoids—Promising Tools in the Era of Personalized Medicine
por: Colella, Gianluca, et al.
Publicado: (2018)

Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients
por: Tanaka, Kazuhiro, et al.
Publicado: (2016)

Nomograms predicting local and distant recurrence and disease-specific mortality for R0/R1 soft tissue sarcomas of the extremities
por: De Sanctis, Rita, et al.
Publicado: (2022)

Measuring Regional Performance in the Italian NHS: Are Disparities Decreasing?
por: Bruzzi, Silvia, et al.
Publicado: (2021)

Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
por: Palmerini, E., et al.
Publicado: (2016)

Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
por: Pender, Alexandra, et al.
Publicado: (2018)

Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study
por: Hara, Hitomi, et al.
Publicado: (2019)

Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma
por: Pan, Minggui, et al.
Publicado: (2021)

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma
por: De Sanctis, Rita, et al.
Publicado: (2015)

Lack of immunity against rubella among Italian young adults
por: Serena, Gallone Maria, et al.
Publicado: (2017)

Identification, molecular characterization and segregation analysis of a variant DMPK pre-mutation allele in a three-generation Italian family
por: Fontana, Luana, et al.
Publicado: (2020)

Response of follicular dendritic cell sarcoma to gemcitabine and docetaxel: report of two cases and literature review
por: Conry, Robert M
Publicado: (2014)

Conflict of interest among Italian medical oncologists: a national survey
por: DeCensi, Andrea, et al.
Publicado: (2018)

A Pharmacological Analysis of the Activity and Failure of the Medical Treatment of High-Grade Osteosarcoma
por: Comandone, Alessandro, et al.
Publicado: (2021)

Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results
por: Comandone, Alessandro, et al.
Publicado: (2021)

Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis
por: Takahashi, Masanobu, et al.
Publicado: (2017)

A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors
por: Yoon, Jong Hyung, et al.
Publicado: (2014)

RCBTB1 Deletion Is Associated with Metastatic Outcome and Contributes to Docetaxel Resistance in Nontranslocation-Related Pleomorphic Sarcomas
por: Mauduit, Olivier, et al.
Publicado: (2019)

Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study
por: Narayanan, Prasad, et al.
Publicado: (2019)

Erratum to: lack of immunity against rubella among Italian young adults
por: Gallone, Maria Serena, et al.
Publicado: (2017)

Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system
por: Galeone, Carlotta, et al.
Publicado: (2021)

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas
por: Jones, Robin L., et al.
Publicado: (2019)

Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
por: Tanaka, Kazuhiro, et al.
Publicado: (2022)

LACK OF DISTINCTIVE SURFACE ANTIGEN ON CELLS TRANSFORMED BY MURINE SARCOMA VIRUS
por: Strouk, Vladimir, et al.
Publicado: (1972)

Activity of regorafenib in advanced pretreated soft tissue sarcoma: Results of a single-center phase II study
por: Marrari, Andrea, et al.
Publicado: (2020)

A Case of Ocular Kaposi’s Sarcoma Successfully Treated with Highly Active Antiretroviral Therapy (HAART) Combined with Docetaxel
por: Jin, Chongfei, et al.
Publicado: (2018)

Docetaxel loaded mPEG-PLA nanoparticles for sarcoma therapy: preparation, characterization, pharmacokinetics, and anti-tumor efficacy
por: Chen, Jianhua, et al.
Publicado: (2021)

A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma
por: Tansir, Ghazal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_37nf7k2hrm7bt10tpm670mtctk